| Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ... Cell 161 (7), 1681-1696, 2015 | 2667 | 2015 |
| Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery J Kao, K Salari, M Bocanegra, YL Choi, L Girard, J Gandhi, KA Kwei, ... PloS one 4 (7), e6146, 2009 | 924 | 2009 |
| The somatic genomic landscape of chromophobe renal cell carcinoma CF Davis, CJ Ricketts, M Wang, L Yang, AD Cherniack, H Shen, C Buhay, ... Cancer cell 26 (3), 319-330, 2014 | 807 | 2014 |
| Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma N Kim, HK Kim, K Lee, Y Hong, JH Cho, JW Choi, JI Lee, YL Suh, BM Ku, ... Nature communications 11 (1), 2285, 2020 | 665 | 2020 |
| Early osteolysis following second-generation metal-on-metal hip replacement YS Park, YW Moon, SJ Lim, JM Yang, G Ahn, YL Choi JBJS 87 (7), 1515-1521, 2005 | 415 | 2005 |
| Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement SM Lim, HR Kim, JS Lee, KH Lee, YG Lee, YJ Min, EK Cho, SS Lee, ... Journal of clinical oncology 35 (23), 2613-2618, 2017 | 350 | 2017 |
| Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial J Cho, HS Kim, BM Ku, YL Choi, R Cristescu, J Han, JM Sun, SH Lee, ... J clin oncol 37 (24), 2162-70, 2019 | 259 | 2019 |
| Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non … JS Ahn, YC Ahn, JH Kim, CG Lee, EK Cho, KC Lee, M Chen, DW Kim, ... J Clin Oncol 33 (24), 2660-6, 2015 | 255 | 2015 |
| Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ KM Joo, J Kim, J Jin, M Kim, HJ Seol, J Muradov, H Yang, YL Choi, ... Cell reports 3 (1), 260-273, 2013 | 245 | 2013 |
| Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer KA Kwei, YH Kim, L Girard, J Kao, M Pacyna-Gengelbach, K Salari, J Lee, ... Oncogene 27 (25), 3635-3640, 2008 | 241 | 2008 |
| Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management HY Lee, YL Choi, KS Lee, J Han, JI Zo, YM Shim, JW Moon American Journal of Roentgenology 202 (3), W224-W233, 2014 | 225 | 2014 |
| Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial SH Lee, JK Lee, MJ Ahn, DW Kim, JM Sun, B Keam, TM Kim, DS Heo, ... Annals of Oncology 28 (2), 292-297, 2017 | 215 | 2017 |
| Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients Y Kim, PS Hammerman, J Kim, J Yoon, Y Lee, JM Sun, MD Wilkerson, ... Journal of clinical oncology 32 (2), 121, 2014 | 213 | 2014 |
| Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma TY Na, YK Shin, KJ Roh, SA Kang, I Hong, SJ Oh, JK Seong, CK Park, ... Hepatology 49 (4), 1122-1131, 2009 | 190 | 2009 |
| BRAF V600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAF V600E-prevalent population SW Kim, JI Lee, JW Kim, CS Ki, YL Oh, YL Choi, JH Shin, HK Kim, ... The Journal of Clinical Endocrinology & Metabolism 95 (8), 3693-3700, 2010 | 184 | 2010 |
| High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients S Park, YL Choi, CO Sung, J An, J Seo, MJ Ahn, JS Ahn, K Park, YK Shin, ... F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de …, 2012 | 180 | 2012 |
| Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy ST Kim, DH Lim, KT Jang, T Lim, J Lee, YL Choi, HL Jang, JH Yi, KK Baek, ... Molecular cancer therapeutics 10 (10), 1993-1999, 2011 | 177 | 2011 |
| LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer YL Choi, M Bocanegra, MJ Kwon, YK Shin, SJ Nam, JH Yang, J Kao, ... Cancer research 70 (6), 2296-2306, 2010 | 170 | 2010 |
| Prevalence and detection of low-allele-fraction variants in clinical cancer samples HT Shin, YL Choi, JW Yun, NKD Kim, SY Kim, HJ Jeon, JY Nam, C Lee, ... Nature communications 8 (1), 1377, 2017 | 168 | 2017 |
| Clinical relevance of TNM staging system according to breast cancer subtypes YH Park, SJ Lee, EY Cho, YL Choi, JE Lee, SJ Nam, JH Yang, JH Shin, ... Annals of oncology 22 (7), 1554-1560, 2011 | 166 | 2011 |
